ID CD63_HUMAN STANDARD; PRT; 237 AA. AC P08962; DT 01-NOV-1988 (Rel. 09, Created) DT 01-NOV-1988 (Rel. 09, Last sequence update) DT 29-MAR-2004 (Rel. 43, Last annotation update) DE CD63 antigen (Melanoma-associated antigen ME491) (Lysosome-associated DE membrane glycoprotein 3) (LAMP-3) (Ocular melanoma-associated DE antigen) (OMA81H) (Granulophysin). GN CD63 OR MLA1. OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo. OX NCBI_TaxID=9606; RN [1] RP SEQUENCE FROM N.A. RX MEDLINE=88210273; PubMed=3365686; RA Hotta H., Ross A.H., Huebner K., Isobe M., Wendeborn S., Chao M.V., RA Ricciardi R.P., Tsujimoto Y., Croce C.M., Koprowski H.; RT "Molecular cloning and characterization of an antigen associated with RT early stages of melanoma tumor progression."; RL Cancer Res. 48:2955-2962(1988). RN [2] RP SEQUENCE FROM N.A. RX MEDLINE=91131632; PubMed=1993697; RA Metzelaar M.J., Wigngaard P.L., Peters P.J., Sixma J.J., RA Nieuwenhuis H.K., Clevers H.C.; RT "CD63 antigen. A novel lysosomal membrane glycoprotein, cloned by a RT screening procedure for intracellular antigens in eukaryotic cells."; RL J. Biol. Chem. 266:3239-3245(1991). RN [3] RP SEQUENCE FROM N.A. RC TISSUE=Ovary; RX MEDLINE=91025550; PubMed=2171551; RA Rapp G., Freudenstein J., Klaudiny J., Mucha J., Wempe F., Zimmer M., RA Scheit K.H.; RT "Characterization of three abundant mRNAs from human ovarian RT granulosa cells."; RL DNA Cell Biol. 9:479-485(1990). RN [4] RP SEQUENCE FROM N.A. RX MEDLINE=92287132; PubMed=1599482; RA Hotta H., Miyamoto H., Hara I., Takahashi N., Homma M.; RT "Genomic structure of the ME491/CD63 antigen gene and functional RT analysis of the 5'-flanking regulatory sequences."; RL Biochem. Biophys. Res. Commun. 185:436-442(1992). RN [5] RP SEQUENCE FROM N.A. RX MEDLINE=92181348; PubMed=1339263; RA Wang M.X., Earley J.J. Jr., Shields J.A., Donoso L.A.; RT "An ocular melanoma-associated antigen. Molecular characterization."; RL Arch. Ophthalmol. 110:399-404(1992). RN [6] RP SEQUENCE FROM N.A. RC TISSUE=Lung, and Muscle; RX MEDLINE=22388257; PubMed=12477932; RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G., RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D., RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K., RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F., RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L., RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E., RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C., RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J., RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H., RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W., RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A., RA Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A., RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G., RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C., RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E., RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.; RT "Generation and initial analysis of more than 15,000 full-length RT human and mouse cDNA sequences."; RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002). RN [7] RP SEQUENCE OF 1-20. RX MEDLINE=86049405; PubMed=4062294; RA Ross A.H., Dietzschold B., Jackson D.M., Earley J.J., Ghrist B.F.D., RA Atkinson B., Koprowski H.; RT "Isolation and amino terminal sequencing of a novel RT melanoma-associated antigen."; RL Arch. Biochem. Biophys. 242:540-548(1985). RN [8] RP CARBOHYDRATE-LINKAGE SITE ASN-129. RX MEDLINE=22660472; PubMed=12754519; RA Zhang H., Li X.-J., Martin D.B., Aebersold R.; RT "Identification and quantification of N-linked glycoproteins using RT hydrazide chemistry, stable isotope labeling and mass spectrometry."; RL Nat. Biotechnol. 21:660-666(2003). CC -!- FUNCTION: This antigen is associated with early stages of melanoma CC tumor progression. May play a role in growth regulation. CC -!- SUBCELLULAR LOCATION: Integral membrane protein. Lysosomal. CC -!- TISSUE SPECIFICITY: Dysplastic nevi, radial growth phase primary CC melanomas, hematopoietic cells, tissue macrophages. CC -!- SIMILARITY: Belongs to the tetraspanin (TM4SF) family. CC -!- DATABASE: NAME=PROW; NOTE=CD guide CD63 entry; CC WWW="http://www.ncbi.nlm.nih.gov/prow/cd/cd63.htm". CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X07982; CAA30792.1; -. DR EMBL; M58485; -; NOT_ANNOTATED_CDS. DR EMBL; M59907; AAA63235.1; -. DR EMBL; X62654; CAA44519.1; -. DR EMBL; S93788; AAB21617.1; -. DR EMBL; BC002349; AAH02349.1; -. DR EMBL; BC013017; AAH13017.1; -. DR PIR; I38016; I38016. DR Genew; HGNC:1692; CD63. DR MIM; 155740; -. DR GO; GO:0005887; C:integral to plasma membrane; TAS. DR GO; GO:0005765; C:lysosomal membrane; TAS. DR InterPro; IPR000301; Transmem_4. DR Pfam; PF00335; transmembrane4; 1. DR PRINTS; PR00259; TMFOUR. DR PROSITE; PS00421; TM4_1; 1. KW Glycoprotein; Antigen; Transmembrane; Lysosome. FT INIT_MET 0 0 FT DOMAIN 1 10 Cytoplasmic (Potential). FT TRANSMEM 11 31 Potential. FT DOMAIN 32 50 Extracellular (Potential). FT TRANSMEM 51 69 Potential. FT DOMAIN 70 80 Cytoplasmic (Potential). FT TRANSMEM 81 106 Potential. FT DOMAIN 107 202 Extracellular (Potential). FT TRANSMEM 203 223 Potential. FT DOMAIN 224 237 Cytoplasmic (Potential). FT CARBOHYD 129 129 N-linked (GlcNAc...). FT CARBOHYD 149 149 N-linked (GlcNAc...) (Potential). FT CARBOHYD 171 171 N-linked (GlcNAc...) (Potential). SQ SEQUENCE 237 AA; 25505 MW; 0CBC38F831CF0C9B CRC64; AVEGGMKCVK FLLYVLLLAF CACAVGLIAV GVGAQLVLSQ TIIQGATPGS LLPVVIIAVG VFLFLVAFVG CCGACKENYC LMITFAIFLS LIMLVEVAAA IAGYVFRDKV MSEFNNNFRQ QMENYPKNNH TASILDRMQA DFKCCGAANY TDWEKIPSMS KNRVPDSCCI NVTVGCGINF NEKAIHKEGC VEKIGGWLRK NVLVVAAAAL GIAFVEVLGI VFACCLVKSI RSGYEVM //